Topical retinaldehyde on human skin: biologic effects and tolerance.

The present study was designed to explore if *etinaldehyde, a natural metabolite of vitamin A, has any biologic activity and is tolerated by human skin. Biologic activity was shown by the induction of cellular retinoic acid-binding protein type 2 (CRABP 2) mRNA and protein; the rank order for CRABP-2 increase was retinoic acid > retinaldehyde > 9 cis retinoic acid > retinol > beta carotene. In volunteers treated 1-3 months with 0.5, 0.1, and 0.05% retinaldehyde, there was a dose-dependent and significant increase in epidermal thickness, keratin 14 immunoreactivity, and Ki67-positive cells. The area of distribution of involucrin, transglutaminase, and filaggrin immunoreactivity was also increased in a dose-dependent manner, and keratin 4 immunoreactivity was induced in the upper epidermis. In pilot clinical tolerance studies, 229 patients received topical retinaldehyde at different concentrations; the 1% preparation was tolerated by up to 70% of the treated subjects; tolerance of the 0.5% preparation was slightly better, whereas both 0.1 and 0.05% preparations applied on facial skin were well tolerated and allowed prolonged use (up to 3 years) in patients with inflammatory dermatoses. These findings indicate that topical retinaldehyde has biologic activity and is well tolerated on human skin.

[1]  J. Saurat,et al.  Topical glucocorticosteroids modulate the expression of CRABP I and II in human skin differently , 1994, Experimental dermatology.

[2]  J. Saurat,et al.  Cellular retinoic acid‐binding proteins (CRABP) , 1993, Experimental dermatology.

[3]  James T. Elder,et al.  Comparison of CD271 (adapalene) and all-trans retinoic acid in human skin: dissociation of epidermal effects and CRABP-II mRNA expression. , 1993, The Journal of investigative dermatology.

[4]  C. Redfern.  Role of retinoic acid, a derivative of vitamin A (retinol), in tissue development and maintenance. , 1993, Journal of Investigative Dermatology.

[5]  J. Repa,et al.  All-trans-retinol is a ligand for the retinoic acid receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[6]  James T. Elder,et al.  Stimulus-selective induction of CRABP-II mRNA: a marker for retinoic acid action in human skin. , 1993, The Journal of investigative dermatology.

[7]  J. Saurat,et al.  Expression of CRABP-I and -II in human epidermal cells. Alteration of relative protein amounts is linked to the state of differentiation. , 1992, The Biochemical journal.

[8]  P. Chambon,et al.  All-trans and 9-cis retinoic acid induction of CRABPII transcription is mediated by RAR-RXR heterodimers bound to DR1 and DR2 repeated motifs , 1992, Cell.

[9]  P. Chambon,et al.  Human skin levels of retinoic acid and cytochrome P-450-derived 4-hydroxyretinoic acid after topical application of retinoic acid in vivo compared to concentrations required to stimulate retinoic acid receptor-mediated transcription in vitro. , 1992, The Journal of clinical investigation.

[10]  N. Copeland,et al.  The murine gene for cellular retinoic acid-binding protein type II. Genomic organization, chromosomal localization, and post-transcriptional regulation by retinoic acid. , 1992, The Journal of biological chemistry.

[11]  J. Voorhees,et al.  Acute or chronic topical retinoic acid treatment of human skin in vivo alters the expression of epidermal transglutaminase, loricrin, involucrin, filaggrin, and keratins 6 and 13 but not keratins 1, 10, and 14. , 1992, The Journal of investigative dermatology.

[12]  J. Saurat,et al.  Cellular retinoic acid-binding protein type 2 mRNA is overexpressed in human psoriatic skin as shown by in situ hybridization. , 1991, Biochemical and Biophysical Research Communications - BBRC.

[13]  J. Saurat,et al.  Natural Retinoids:Metabolism and Transport in Human Epidermal Cells1 , 1991 .

[14]  G. Siegenthaler,et al.  Ligand specificities of recombinant retinoic acid receptors RAR alpha and RAR beta. , 1990, The Biochemical journal.

[15]  J. Saurat,et al.  Metabolism of natural retinoids in psoriatic epidermis. , 1990, The Journal of investigative dermatology.

[16]  J. Saurat,et al.  Retinol and retinal metabolism. Relationship to the state of differentiation of cultured human keratinocytes. , 1990, The Biochemical journal.

[17]  M. Lakshman,et al.  Enzymatic conversion of all-trans-beta-carotene to retinal by a cytosolic enzyme from rabbit and rat intestinal mucosa. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Saurat,et al.  Ligand‐specific and non‐specific in vivo modulation of human epidermal cellular retinoic acid binding protein (CRABP) , 1989, European journal of clinical investigation.

[19]  T. Hamilton,et al.  Topical tretinoin improves photoaged skin. A double-blind vehicle-controlled study. , 1988, JAMA.

[20]  J. Saurat,et al.  A slab gel electrophoresis technique for measurement of plasma retinol-binding protein, cellular retinol-binding and retinoic-acid-binding proteins in human skin. , 1987, European journal of biochemistry.

[21]  C. Orfanos,et al.  Retinoic acid in psoriasis: its value for topical therapy with and without corticosteroids , 1973, The British journal of dermatology.

[22]  C. Redfern.  Molecular markers of retinoid activity in skin. , 1994, Journal of Investigative Dermatology.

[23]  J. Saurat,et al.  Topical retinaldehyde on human skin: clinical and biological observations. , 1994 .

[24]  J. Saurat,et al.  Overexpression of cellular retinoic acid-binding protein type II (CRABP-II) and down-regulation of CRABP-I in psoriatic skin. , 1992, Dermatology.

[25]  R. Happle,et al.  Topical treatment with 13-cis-retinoic acid improves Darier's disease and induces the expression of a unique keratin pattern. , 1991, Dermatologica.

[26]  G. Siegenthaler.  Gel electrophoresis of cellular retinoic acid-binding protein, cellular retinol-binding protein, and serum retinol-binding protein. , 1990, Methods in enzymology.